BamSEC and AlphaSense Join Forces
Learn More

Sangamo Therapeutics Inc. – Plans of Reorganization, Merger, Acquisition or Similar

OTC: SGMO    
Share price (6/23/26): $0.07    
Market cap (6/23/26): $30.7 million
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.2
from 8-K/A 72 pages Asset Purchase Agreement by and Between Astellas Gene Therapies, Inc. and Sangamo Therapeutics, Inc. Dated as of June 22, 2026
12/34/56
EX-2.1
from 8-K/A 73 pages Asset Purchase Agreement by and Among Sangamo Therapeutics, Inc., Merope Acquisition Sub, LLC, Eli Lilly and Company, Solely for Purposes of Section 10.21, as the Guarantor and Sangamo Therapeutics Uk Ltd., Sangamo Therapeutics France Sas and Ceregene, Inc., Solely for Purposes of Section 10.22, as the Seller Subsidiaries Dated as of June 22, 2026
12/34/56
EX-2.4
from 8-K 27 pages Amendment No. 1 to the Tender Offer Agreement Between Txcell S.A. and Sangamo Therapeutics, Inc. Dated as of October 1st, 2018
12/34/56
EX-2.2
from 8-K 16 pages From: The Sellers. To: Sangamo Therapeutics, Inc. 501 Canal Blvd, Richmond Ca 94804 United States of America October 1st, 2018 Amendment Agreement to the Spa (The “Amendment Agreement”) Dear Sirs,
12/34/56
EX-2.2
from 8-K 29 pages Tender Offer Agreement Between Txcell S.A. and Sangamo Therapeutics, Inc. Dated as of July 20, 2018
12/34/56
EX-2.1
from 8-K 24 pages Share Purchase Agreement
12/34/56
EX-2.1
from 8-K 71 pages Agreement and Plan of Merger by and Among Sangamo Biosciences, Inc. Cg Acquisition Sub, Inc. and Ceregene, Inc. and Hamilton Bioventure Services, Inc., as Stockholders’ Representative Dated as of August 23, 2013
12/34/56
EX-2.1
from 8-K 46 pages Asset Purchase Agreement
12/34/56
EX-2.1
from 8-K ~50 pages Dated June 28, 2001 the Sellers Named in Schedule 1a and Sangamo Biosciences Inc. Agreement for the Sale and Purchase of All the Issued Share Capital of Gendaq Limited Brobeck Hale and Dorr Alder Castle 10 Noble Street London Ec2v 7qj Tel: +44 (0)20 7645 2400 Fax: +44 (0)20 7645 2424 Contents
12/34/56